Disclosed is the use of D-threo methylphenidate, or a salt thereof, that is substantially free of both the 1-threo isomer and salts thereof and the erythro methylphenidates and salts thereof, to treat a disease or disorder selected from: attention deficit-hyperactivity disorder (ADHD), symptoms associated with menopause, or one or more of a decrease on cognitive function, fatigue, neurobehavioral slowing that is unrelated to the administration of analgesics, but may be related to an underlying cancer, the treatment of the cancer, or both, neurobehavioral slowing and cognitive side effects arising from cancer, or from a treatment therefor, including chemotherapy, radiation therapy, administration of medication to control pain, or neurobehavioral slowing arising from the administration of treatment for oncological condition, in a patient suffering from Tourette syndrome or tics or having a family history of Tourette syndrome or tics.
Treatment of various conditions of patients with Tourette syndrome, tics, or a family history thereof sing D-threo methylphenidate free from other isomers